Alpha Tau Medical Ltd., (DRTS) News
Filter DRTS News Items
DRTS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
DRTS News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest DRTS News From Around the Web
Below are the latest news stories about ALPHA TAU MEDICAL LTD that investors may wish to consider to help them evaluate DRTS as an investment opportunity.
US Penny Stocks To Consider In January 2025As we step into January 2025, the U.S. stock market is experiencing a downturn with major indices like the S&P 500 and Nasdaq Composite sliding due to rising Treasury yields and mixed economic data. In this climate, investors often look for opportunities in less conventional areas such as penny stocks, which can offer growth potential at lower price points despite their historical reputation as high-risk investments. While the term "penny stock" may seem outdated, these smaller or newer... |
Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update DayJERUSALEM, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that an abstract entitled “Interim analysis of feasibility, safety, and tumor control in two first-in-human trials of a novel alpha-emitting radionuclide for pancreatic adenocarcinoma,” submitted by principal investigators involved in the Company’s Israeli pancreatic cancer trial, has |
Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as AdvisorJERUSALEM, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that following its Annual General Meeting of Company shareholders in Jerusalem, Ms. Maya Netser has been appointed to the Company’s Board of Directors (“Board”). Mr. Meir Jakobsohn is completing his term on the Board, having decided not to pursue re-election, but will continue to serv |
Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceThe overview presentation will review some of the Company’s recent achievements as well as the outlook for upcoming data milestonesJERUSALEM, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CEO Uzi Sofer and CFO Raphi Levy will present a corporate overview and update at the J.P. Morgan 43rd Annual Healthcare Conference on Thursday, Janua |
Alpha Tau to Participate in Ladenburg’s Oncology Innovators & Investors SymposiumJERUSALEM, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will present at the Ladenburg Oncology Innovators & Investors Symposium. Event:Ladenburg Oncology Innovators & Investors SymposiumFormat:Presentation and 1-on-1 MeetingsDate:December 12, 2024Time:11:00AM – 11:25AM ESTLocation:Virtual Please reach out to your Ladenb |
3 Promising Penny Stocks In The US With Market Caps Under $400MAs the U.S. stock market reaches record highs, with indices like the S&P 500 and Dow Jones posting their biggest monthly gains of 2024, investors are exploring opportunities beyond well-known large-cap stocks. Penny stocks, often representing smaller or newer companies, continue to intrigue investors despite their vintage name. This article will spotlight several penny stocks that stand out for their financial strength and potential for long-term success amidst current market conditions. |
Alpha Tau Medical Announces Third Quarter 2024 Financial Results and Provides Corporate Update- Alpha DaRT® accepted into the prestigious Total Product Life Cycle Advisory Program (TAP) of the FDA, to accelerate market access to the Alpha DaRT® for patients with recurrent glioblastoma multiforme (GBM) - - First patient treated in Recurrent Lung Cancer study in Israel, which will assess the safety and feasibility of delivering Alpha DaRT® sources into the lung using an endobronchial ultrasound procedure - - FDA approval of an Investigational Device Exemption (IDE) application to initiate |
Alpha Tau to Participate in Citi’s 2024 Global Healthcare Conference and Piper Sandler’s 36th Annual Healthcare ConferenceJERUSALEM, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will participate in the Citi 2024 Global Healthcare Conference on December 3rd, 2024 and the Piper Sandler 36th Annual Healthcare Conference on December 5th, 2024. Event:Citi 2024 Global Healthcare ConferenceFormat:1-on-1 MeetingsDate:December 3, 2024Time:8:30AM – |
Discover Alpha Tau Medical And 2 Other US Penny StocksThe U.S. stock market has recently experienced a rally, driven by strong earnings from major tech companies and a steady jobs report, which have bolstered investor confidence despite recent fluctuations. Amidst these broader market dynamics, the concept of penny stocks remains relevant for those seeking affordable entry points into potentially high-growth investments. These stocks often represent smaller or newer companies and can offer significant value when supported by robust financials... |
Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma MultiformeJERUSALEM, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-emitters cancer therapy Alpha DaRT®, announced today that it has been accepted into the prestigious Total Product Life Cycle (TPLC) Advisory Program (“TAP”) Pilot of the U.S. Food and Drug Administration (“FDA”), to accelerate market access to the Alpha DaRT for patients with recurrent glioblastoma multiforme (“GBM”). This acceptance fol |